Page 426 - Read Online

Cerna et al. Nanodrugs in brain tumors

radioiodinated recombinant protein in the rhesus monkey. Bioconjug therapy of glioblastoma stem-like cells and tumor non-stem cells
Chem 2013;24:1741-9. using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget
62. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR. Tumor-targeting dual 2015;6:8788-806.
peptides-modified cationic liposomes for delivery of siRNA and 72. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD,
docetaxel to gliomas. Biomaterials 2014;35:5226-39. Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM,
63. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen
nanoparticles for the potential treatment of brain tumors. J Control PY. Phase I study of GRN1005 in recurrent malignant glioma. Clin
Release 2004;99:259-69. Cancer Res 2013;19:1567-76.
64. Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant-coated 73. Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM,
poly(methyl methacrylate)-nanoparticles by bovine brain microvessel Kalkanis SN, Whitsett TG, Salhia B, Tran NL, Ryken T, Moore MK,
endothelial cell monolayers. Int J Pharm 1994;110:29-35. Egan KM, Olson JJ. Current approaches to the treatment of metastatic
65. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of brain tumours. Nat Rev Clin Oncol 2014;11:203-22.
the type of surfactant on the analgesic effects induced by the peptide 74. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin
dalargin after its delivery across the blood-brain barrier using conjugate (Tf-CRM107) for therapy of malignant gliomas. J
surfactant-coated nanoparticles. J Control Release 1997;49:81-7. Neurooncol 2003;65:3-13.
66. Kreuter J, Ramge P, Petrov V, Hamm S, Gelprina SE, Engelhardr B, 75. Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental
Alyautdin R, Briesen HV, Begley DJ. Direct evidence that polysorbate- approaches for the treatment of malignant gliomas. Pharmacol Ther
80-coated poly(butyl cyanoacrylate) nanopaticles deliver drugs to the 2010;128:1-36.
CNS via specific mechanisms requiring prior binding of the drug to 76. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S,
the nanoparticles. Pharm Res 2003;20:409-16. Steinbrecher A, Ullrich W, Bogdahn U. Long-term stabilization
67. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, in patients with malignant glioma after treatment with liposomal
Kreuter J. Significant transport of doxorubicin into the brain with doxorubicin. Cancer 2001;92:1936-42.
polysorbate 80-coated nanoparticles. Pharm Res 1999;16:1564-9. 77. Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A,
68. Jain A, Jain A, Garg NK, Tyagi RK, Singh B, Katare OP, Webster Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hübner F, Jauch
TJ, Soni V. Surface engineered polymeric nanocarriers mediate the T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A,
delivery of transferrin-methotrexate conjugates for an improved Steinbrecher A, Marienhagen J, Bogdahn U. Pegylated liposomal
understanding of brain cancer. Acta Biomater 2015; 24:140-51. doxorubicin-efficacy in patients with recurrent high-grade glioma.
69. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Cancer 2004;100:1199-207.
Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina 78. Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors
SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded using nanocarriers. Biomaterials 2007;28:4947-67.
nanoparticles. Int J Cancer 2004;109:759-67. 79. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle
70. Householder KT, DiPerna DM, Chung EP, Wohlleb GM, Dhruv HD, technology for drug delivery across the blood-brain barrier. Drug Dev
Berens ME, Sirianni RW. Intravenous delivery of camptothecin- Ind Pharm 2002;28:1-13.
loaded PLGA nanoparticles for the treatment of intracranial glioma. 80. Pillai G. Nanomedicines for cancer therapy: an update of FDA
Int J Pharm 2015;479:374-80. approved and those under various stages of development. SOJ Pharm
71. Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted Pharm Sci 2014;1:13-25.

416 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ October 31, 2016